Protein therapeutics – lessons learned and a view of the future

Bibliography

• CLARKE JT, IWANOCHKO RM: Enzyme replacement therapy of Fabry disease. Mol. Neurobiol. (2005) 32:43-50.
   PubMed Web of Science ®Google Scholar
• LABRIOLA-TOMPKINS E, CHANDRAN C, KAFFKA KL et al.: Identification of the discontinuous binding site in human interleukin 1 beta for the Type I interleukin 1 receptor. Proc. Natl. Acad. Sci. USA (1991) 88:11182-11186.
   PubMed Web of Science ®Google Scholar
• CARTER DB, DEIBEL MR JR, DUNN CJ et al.: Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature (1990) 344:633-638.
   PubMed Web of Science ®Google Scholar
• GRANOWITZ EV, CLARK BD, MANCILLA J, DINARELLO CA: Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the Type II interleukin-1 receptor. J. Biol. Chem. (1991) 266:14147-14150.
   PubMed Web of Science ®Google Scholar
• NOVICK D, KIM SH, FANTUZZI G, REZNIKOV LL, DINARELLO CA, RUBINSTEIN M: Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 10:127-136.
   PubMed Web of Science ®Google Scholar
• NOVICK D, ENGELMANN H, WALLACH D, LEITNER O, REVEL M, RUBINSTEIN M: Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J. Chromatogr. (1990) 510:331-337.
   PubMed Web of Science ®Google Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
   PubMed Web of Science ®Google Scholar
• HWANG WY, FOOTE J: Immunogenicity of engineered antibodies. Methods (2005) 36:3-10.
   PubMed Web of Science ®Google Scholar
• CHOWDHURY PS, WU H: Tailor-made antibody therapeutics. Methods (2005) 36:11-24.
   PubMed Web of Science ®Google Scholar
  •A recent review that discusses the evolution of antibodies from murine to fully human, and how antibody engineering technologies may be employed to generate antibodies with defined specificity, affinity and effector functions.
   Google Scholar
• STOCKS MR: Intrabodies: production and promise. Drug Discov. Today (2004) 9:960-966.
   PubMed Web of Science ®Google Scholar
• HENG BC, KEMENY DM, LIU H, CAO T: Potential applications of intracellular antibodies (intrabodies) in stem cell therapeutics. J. Cell Mol. Med. (2005) 9:191-195.
   PubMed Web of Science ®Google Scholar
• LUCAS A, MCFADDEN G: Secreted immunomodulatory viral proteins as novel biotherapeutics. J. Immunol. (2004) 173:4765-4774.
   PubMed Web of Science ®Google Scholar
  ••This article cites the current state of non-human protein therapeutics.
   Google Scholar
• ALCAMI A: Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. (2003) 3:36-50.
   PubMed Web of Science ®Google Scholar
  ••Excellent review of virally encoded immunomodulatory proteins.
   Google Scholar
• ROLLINS BJ: Chemokines. Blood (1997) 90:909-928.
   PubMed Web of Science ®Google Scholar
• FOXMAN EF, CAMPBELL JJ, BUTCHER EC: Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. (1997) 139:1349.
   PubMed Web of Science ®Google Scholar
• LUCAS A, LIU L, MACEN J et al.: Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation (1996) 94:2890-2900.
   PubMed Web of Science ®Google Scholar
• LIU L, DAI E, MILLER L et al.: Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation (2004) 77:1652-1660.
   PubMed Web of Science ®Google Scholar
• PAESEN GC, ADAMS PL, HARLOS K, NUTTALL PA, STUART DI: Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol. Cell (1999) 3:661-671.
   PubMed Web of Science ®Google Scholar
• HAJNICKA V, VANCOVA I, KOCAKOVA P et al.: Manipulation of host cytokine network by ticks: a potential gateway for pathogen transmission. Parasitology (2005) 130:333-342.
   PubMed Web of Science ®Google Scholar
• GREINACHER A, EICHLER P, ALBRECHT D, STROBEL U, POTZSCH B, ERIKSSON BI: Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood (2003) 101:2617-2619.
   PubMed Web of Science ®Google Scholar
• SCHELLEKENS H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. (2002) 1:457-462.
   Google Scholar
  •A very interesting review that discusses the factors that influence immunogenicity.
   Google Scholar
• PORTER S: Human immune response to recombinant human proteins. J. Pharm. Sci. (2001) 90:1-11.
   PubMed Web of Science ®Google Scholar
• BICHLER J, GEMMERLI R, FRITZ H: Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons. Thromb. Res. (1991) 61:39-51.
   PubMed Web of Science ®Google Scholar
• BUGELSKI PJ, TREACY G: Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. (2004) 6:10-16.
   PubMed Web of Science ®Google Scholar
  ••An excellent article that reviews the value and limitation of testing for immunogenicity in animal models.
   Google Scholar
• BUSSIERE JL: Animal models as indicators of immunogenicity of therapeutic proteins in humans. Dev. Biol. (Basel) (2003) 112:135-139.
   PubMedGoogle Scholar
• ZEUZEM S, FEINMAN SV, RASENACK J et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. (2000) 343:1666-1672.
   PubMed Web of Science ®Google Scholar
• PRESTA LG, SHIELDS RL, NAMENUK AK, HONG K, MENG YG: Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans. (2002) 30:487-490.
   PubMed Web of Science ®Google Scholar
• GRIBBEN JG, DEVEREUX S, THOMAS NS et al.: Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet (1990) 335:434-437.
   PubMed Web of Science ®Google Scholar
• CASADEVALL N, NATAF J, VIRON B et al.: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. (2002) 346:469-475.
   PubMed Web of Science ®Google Scholar
  •An important study documenting the crossreactivity of antidrug antibodies with an endogenous protein thereby leading to a serious life-threatening condition. This was perhaps the first case study to bring the potential risks of immunogenicity of biologics to the forefront.
   Google Scholar
• MATZINGER P: An innate sense of danger. Semin. Immunol. (1998) 10:399-415.
   PubMed Web of Science ®Google Scholar
• KAISHO T, AKIRA S: Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta (2002) 1589:1-13.
   PubMed Web of Science ®Google Scholar
• AKIRA S, HEMMI H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. (2003) 85:85-95.
   PubMed Web of Science ®Google Scholar
• DRESSER DW: Specific inhibition of antibody production. I. Protein-over loading paralysis. Immunology (1962) 5:161-168.
   PubMed Web of Science ®Google Scholar
• GAMBLE CN: The role of soluble aggregates in the primary immune response of mice to human gamma globulin. Int. Arch. Allergy Appl. Immunol. (1966) 30:446-455.
   PubMedGoogle Scholar
• CHIRINO AJ, ARY ML, MARSHALL SA: Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today (2004) 9:82-90.
   PubMed Web of Science ®Google Scholar
  •A very comprehensive review that covers the topic of immunogenicity in detail, including the way in which antidrug antibodies are produced, how they are detected in patients, models for preclinical screening and some ways in which immunogenicity may be reduced.
   Google Scholar
• WINSOR-HINES D, MERRILL C, O’MAHONY M et al.: Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J. Immunol. (2004) 173:4715-4723.
   PubMed Web of Science ®Google Scholar
• RYDEL TJ, RAVICHANDRAN KG, TULINSKY A et al.: The structure of a complex of recombinant hirudin and human alpha-thrombin. Science (1990) 249:277-280.
   PubMed Web of Science ®Google Scholar